In BRAF-mutant colon cancer, cell resistance to vemurafenib (a BRAF inhibitor) is a result of the feedback activation for the MAPK signaling pathway by SEs, and an additional combination of related inhibitors can reverse this phenomenon [139]. Here, BRAF is linked to colonic neoplasm.